# Professor Nicholas Economides provides perspective on the regulatory impact of the ruling in the AT&T and Time Warner merger

1 Faculty News March 16, 2018 ![The Washington Post logo](/sites/default/files/styles/246w/public/assets/images/con_031074.jpg?itok=f6OME_Rm)>

Excerpt from [The Washington Post](https://www.washingtonpost.com/business/economy/the-atandt-trial-could-curb-mega-mergers--or-weaken-regulators-for-decades/2018/03/15/7906106a-279a-11e8-874b-d517e912f125_story.html?utm_term=.00998f147b55) -- "The antitrust debate is giving pause to business leaders nationwide, analysts say, particularly in the health-care sector, where a bevy of recent cross-industry deals could raise similar regulatory issues. CVS’s $69 billion acquisition of the health insurer Aetna, as well as Cigna’s $52 billion purchase of Express Scripts, could both be affected by the AT&T trial, analysts say. 'If the government wins this case, they would be concerned,' said [Nicholas Economides](http://www.stern.nyu.edu/faculty/bio/nicholas-economides), an economics professor at New York University’s Stern School of Business."

[Read more](https://www.washingtonpost.com/business/economy/the-atandt-trial-could-curb-mega-mergers--or-weaken-regulators-for-decades/2018/03/15/7906106a-279a-11e8-874b-d517e912f125_story.html?utm_term=.00998f147b55)